MTOR and neoplasm: For patients with advanced GEP-NETs, the treatment landscape has significantly evolved, integrating targeted therapies such as mTOR inhibitors, such as everolimus, and tyrosine kinase inhibitors (TKIs), such as sunitinib, which have shown effectiveness in blocking key molecular pathways that drive tumor growth, as evidenced by clinical trials, such as the RADIANT studies [79].